AMINOSYN II 5%

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AMINOSYN II 5% (AMINOSYN II 5%).

How it works

Aminosyn II 5% provides essential and non-essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair. It supports metabolic processes in patients unable to maintain adequate nutrition enterally.

What the body does with it

Metabolism	Amino acids are primarily metabolized in the liver via transamination, deamination, and ureagenesis. Bypassing first-pass metabolism when administered intravenously.
Excretion	Renal elimination of amino acids is minimal under normal conditions; excess amino acids are metabolized, and nitrogen is excreted as urea (renal, ~80-90%) and ammonia. Biliary/fecal excretion negligible.
Half-life	Not applicable as a single entity; individual amino acids have variable half-lives (e.g., 10-30 min for most), reflecting rapid distribution and metabolism. Clinical context: continuous infusion maintains steady state.
Protein binding	<5% for most amino acids; limited binding to albumin or specific transport proteins (e.g., tryptophan binds albumin ~10%).
Volume of Distribution	Variable by amino acid; total body water distribution: ~0.5 L/kg for most neutral amino acids, with higher Vd (e.g., 1-2 L/kg) for branched-chain amino acids indicating extensive tissue uptake.
Bioavailability	Intravenous: 100%. Not administered orally; oral bioavailability of intact amino acids is not applicable for this product.
Onset of Action	Intravenous: Immediate upon infusion; plasma amino acid levels rise within minutes, supporting protein synthesis as soon as infusion starts.
Duration of Action	Intravenous: Duration depends on infusion rate; after cessation, plasma levels decline rapidly (t½ ~10-30 min). Clinical note: Continuous infusion required for sustained effect in parenteral nutrition.

Classification & Brands

Dosing & administration

Intravenous infusion via central line, initial rate 50 mL/hour, increase by 25 mL/hour every 24 hours to goal rate of 1-2 mL/kg/hour (maximum 125 mL/hour). Total daily dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 30-40 mL/kg/day).

Dosage form	INJECTABLE
Renal impairment	GFR 30-59 mL/min: reduce dose by 50%; GFR 15-29 mL/min: reduce dose by 75%; GFR <15 mL/min: contraindicated due to risk of severe uremia. Monitor serum urea and electrolytes closely.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% (target 0.5-1.0 g/kg/day amino acids); Child-Pugh C: avoid use due to risk of hepatic encephalopathy; use with hepatic amino acid formulations.
Pediatric use	Initial dose 1.5-2.0 g/kg/day amino acids, increase by 0.5 g/kg/day up to 2.5-3.0 g/kg/day. Infuse intravenously via central line at 0.1-0.2 mL/kg/hour, titrate to tolerance. Ensure non-protein energy provided concurrently.
Geriatric use	Start at lower end of adult dose (0.5-1.0 g/kg/day amino acids) with gradual escalation. Monitor renal function and fluid status; adjust dose for GFR per renal adjustment. Avoid in severe debility with fluid overload.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for AMINOSYN II 5% (AMINOSYN II 5%).

Breastfeeding

Aminosyn II 5% is considered compatible with breastfeeding. It is a mixture of amino acids, which are normally present in breast milk. The M/P ratio is not applicable as amino acids are endogenous. Use with caution only if clearly needed and monitor for potential adverse effects in the infant such as metabolic acidosis.

Teratogenic Risk

Aminosyn II 5% is an amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no teratogenic effects were observed at clinically relevant doses. Fetal risks are considered low when used as indicated, but parenteral nutrition should only be administered during pregnancy if clearly needed. First trimester: Limited data, theoretical risk of metabolic disturbances; second and third trimesters: No specific fetal risks identified with appropriate use.

Warnings & precautions

■ FDA Black Box Warning

None. However, caution is advised in patients with renal or hepatic impairment; use may require dose adjustments.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Inborn errors of amino acid metabolism","Severe hepatic failure with hyperammonemia","Severe renal failure without adequate dialysis","Anuria","Known hypersensitivity to any component"]

Clinical Precautions

Precautions	["Risk of metabolic acidosis (especially in patients with impaired renal function)","Hepatic steatosis or cholestasis with prolonged TPN","Electrolyte imbalances due to simultaneous administration without monitoring","Infection risk from central line if used for TPN","Monitor serum ammonia levels in patients with hepatic insufficiency"]
Food/Dietary	No direct food interactions due to parenteral administration. However, monitor overall nutritional intake as this solution provides only amino acids; additional carbohydrates, fats, electrolytes, and vitamins are typically co-administered.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

AMINOSYN II 5%

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AMINOSYN II 5% (AMINOSYN II 5%).

How it works

What the body does with it

Metabolism	Amino acids are primarily metabolized in the liver via transamination, deamination, and ureagenesis. Bypassing first-pass metabolism when administered intravenously.
Excretion	Renal elimination of amino acids is minimal under normal conditions; excess amino acids are metabolized, and nitrogen is excreted as urea (renal, ~80-90%) and ammonia. Biliary/fecal excretion negligible.
Half-life	Not applicable as a single entity; individual amino acids have variable half-lives (e.g., 10-30 min for most), reflecting rapid distribution and metabolism. Clinical context: continuous infusion maintains steady state.
Protein binding	<5% for most amino acids; limited binding to albumin or specific transport proteins (e.g., tryptophan binds albumin ~10%).
Volume of Distribution	Variable by amino acid; total body water distribution: ~0.5 L/kg for most neutral amino acids, with higher Vd (e.g., 1-2 L/kg) for branched-chain amino acids indicating extensive tissue uptake.
Bioavailability	Intravenous: 100%. Not administered orally; oral bioavailability of intact amino acids is not applicable for this product.
Onset of Action	Intravenous: Immediate upon infusion; plasma amino acid levels rise within minutes, supporting protein synthesis as soon as infusion starts.
Duration of Action	Intravenous: Duration depends on infusion rate; after cessation, plasma levels decline rapidly (t½ ~10-30 min). Clinical note: Continuous infusion required for sustained effect in parenteral nutrition.

Classification & Brands

Dosing & administration

Dosage form	INJECTABLE
Renal impairment	GFR 30-59 mL/min: reduce dose by 50%; GFR 15-29 mL/min: reduce dose by 75%; GFR <15 mL/min: contraindicated due to risk of severe uremia. Monitor serum urea and electrolytes closely.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% (target 0.5-1.0 g/kg/day amino acids); Child-Pugh C: avoid use due to risk of hepatic encephalopathy; use with hepatic amino acid formulations.
Pediatric use	Initial dose 1.5-2.0 g/kg/day amino acids, increase by 0.5 g/kg/day up to 2.5-3.0 g/kg/day. Infuse intravenously via central line at 0.1-0.2 mL/kg/hour, titrate to tolerance. Ensure non-protein energy provided concurrently.
Geriatric use	Start at lower end of adult dose (0.5-1.0 g/kg/day amino acids) with gradual escalation. Monitor renal function and fluid status; adjust dose for GFR per renal adjustment. Avoid in severe debility with fluid overload.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for AMINOSYN II 5% (AMINOSYN II 5%).

Breastfeeding

Teratogenic Risk

Warnings & precautions

■ FDA Black Box Warning

None. However, caution is advised in patients with renal or hepatic impairment; use may require dose adjustments.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Inborn errors of amino acid metabolism","Severe hepatic failure with hyperammonemia","Severe renal failure without adequate dialysis","Anuria","Known hypersensitivity to any component"]

Clinical Precautions

Precautions	["Risk of metabolic acidosis (especially in patients with impaired renal function)","Hepatic steatosis or cholestasis with prolonged TPN","Electrolyte imbalances due to simultaneous administration without monitoring","Infection risk from central line if used for TPN","Monitor serum ammonia levels in patients with hepatic insufficiency"]
Food/Dietary	No direct food interactions due to parenteral administration. However, monitor overall nutritional intake as this solution provides only amino acids; additional carbohydrates, fats, electrolytes, and vitamins are typically co-administered.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

Clinical Pearls	AMINOSYN II 5% is an amino acid solution for parenteral nutrition. Monitor serum electrolytes, blood urea nitrogen (BUN), and ammonia levels. Use with caution in patients with hepatic or renal impairment. Administer via central line to avoid thrombophlebitis. Do not infuse simultaneously with blood products through same line.
Patient Advice	This medication is given intravenously to provide protein when you cannot eat. · Report any signs of infection at the IV site: redness, swelling, or pain. · You may need regular blood tests to monitor kidney and liver function. · Do not adjust the infusion rate; let the healthcare provider manage it. · Inform your doctor if you have liver or kidney disease.